- Home
- ACRS vs BSRR Comparison
ACRS vs BSRR Comparison
Compare ACRS & BSRR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ACRS | BSRR |
|---|---|---|
| Founded | 2012 | 1977 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 529.9M | 532.1M |
| IPO Year | 2015 | 2001 |
Fundamental Metrics
Financial Performance| Metric | ACRS | BSRR |
|---|---|---|
| Price | $3.33 | $39.56 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 12 | 5 |
| Target Price | $10.18 | ★ $43.00 |
| AVG Volume (30 Days) | ★ 3.5M | 40.3K |
| Earning Date | 11-05-2026 | 10-30-2026 |
| Dividend Yield | N/A | ★ 2.76% |
| EPS Growth | ★ 69.01 | 10.28 |
| EPS | N/A | ★ 1.72 |
| Revenue | ★ $1,683,000.00 | N/A |
| Revenue This Year | N/A | $0.85 |
| Revenue Next Year | N/A | $3.64 |
| P/E Ratio | ★ N/A | $22.76 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.93 | $26.49 |
| 52 Week High | $6.60 | $43.13 |
Technical Indicators
Market Signals| Indicator | ACRS | BSRR |
|---|---|---|
| Relative Strength Index (RSI) | 28.14 | 49.83 |
| Support Level | $3.16 | $39.05 |
| Resistance Level | $3.44 | $41.06 |
| Average True Range (ATR) | 0.33 | 0.91 |
| MACD | -0.08 | 0.02 |
| Stochastic Oscillator | 6.31 | 61.50 |
Price Performance
Historical ComparisonAbout ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.
About BSRR Sierra Bancorp
Sierra Bancorp is a California-based bank holding company, which offers a range of retail and commercial banking services. It offers a wide range of deposit products and services for individuals and businesses including checking accounts, savings accounts, money market demand accounts, time deposits, retirement accounts, and sweep accounts. The company's lending activities cover real estate, commercial (including small business), mortgage warehouse, agricultural and consumer loans, and also offers commercial construction loans and multifamily and agricultural credit facilities among other types of real estate loans.